Critical Observations from Collaborators

Psychedelic therapy access will not be solved by one approval route or one funding model. This page brings together stakeholder perspectives on commercial strategy, health-system readiness, policy, advocacy, and country-level implementation.

The contributors include Martin Gisby of Magnetar Access on commercial strategy, Floris Wolswijk of Blossom on the Netherlands, Josh Hardman of Psychedelic Alpha on market access, Tadeusz Hawrot of PAREA on advocacy, and Viktor Chvátal and Sumudu Gouri Boyina of PsychedelicsEUROPE on country-specific policy.

Read these essays as stress tests for the field. They show where access plans can fail: unclear payer strategy, weak delivery capacity, unrealistic scale assumptions, and policy models that do not translate cleanly across countries.

Together, the pieces show what practical integration would require after the clinical and regulatory case is made.

Commercial strategy: reduce reimbursement risk

Martin Gisby

Commercial development is one route to broad legal access, but it is not the only actor in the field. Psychedelic research also depends on nonprofits, charities, philanthropy, universities, and public funders. The practical question is which groups can carry a therapy through authorisation, reimbursement, clinician support, and safe use across countries.

Even nonprofit approaches need a working access model. Someone has to fund authorisation work, maintain licences, support clinicians, and negotiate price and reimbursement across Europe. The sections below focus on the trade-offs developers face when therapeutic potential meets market-access reality.

Choose the patient population early

The target patient population shapes both the clinical program and the access strategy. A broad indication may reach more people in theory, but it also raises evidence, pricing, budget-impact, and delivery-capacity questions for payers.

When existing care is mostly inexpensive generic medicine, new therapies face pricing pressure. Large eligible populations also create budget-impact concerns. That makes broad indications such as major depressive disorder or generalized anxiety disorder harder to commercialise through European national health systems.

A lower-risk European path may start with smaller populations that have the greatest unmet need and a clearer treatment effect. That can make HTA, pricing, and reimbursement decisions more realistic, even if the long-term ambition is broader access.

Capacity also argues for focus. Even if reimbursement were settled, many countries would not have enough trained sites, referral routes, or clinician confidence to treat large populations quickly after approval.

For Europe, target-population choices should be made early and tested against the future commercial and reimbursement model, not only against the clinical-development plan.

Avoid common European market-access mistakes

Developers should not assume that strong clinical outcomes will automatically lead to reimbursement. Europe has seen medicines with clear efficacy fail to gain access, and psychedelic therapies add extra questions about service delivery, staff time, and administration requirements.

Payers across Europe do not use the same value criteria. They differ on comparators, endpoints, and which outcomes count. That makes early clinical-development choices decisive. Developers need to choose priority launch countries early, then shape Phase II and later evidence plans around those pricing, reimbursement, and market-access expectations, especially in Germany, France, Italy, Spain, and the UK.

European access strategy needs flexibility. Developers may have to tailor target patient groups, clinical positioning, and pricing by country. A rigid demand for the same pathway everywhere can backfire if payers evaluate value through local budgets, comparators, and care pathways.

What is different about psychedelic commercialisation

Several psychedelic-specific uncertainties should stay visible in access planning:

• Several groups are studying the same active ingredients, including psilocybin, LSD, and MDMA. Unlike many medicines, one developer may not control the full commercial field for a substance. That raises practical questions about intellectual property, regulatory exclusivity, pricing, reference pricing, and possible substitution between products.

• Some developers are adapting trial designs to fit regulatory expectations: stronger blinding, leaner psychotherapy components, and endpoints regulators already recognise. That can help approval. It can also widen the gap with payers if the trial does not answer questions about real-world delivery, durability, staffing, and cost. The risk is a therapy that clears regulators but struggles to win reimbursement.

• Drug scheduling and rescheduling processes differ by country. Market-access plans need to account for how those processes work, how long they take, and which implementation barriers remain after rescheduling.

Psychedelic therapy also asks more from the system than a standard medicine: an acutely psychoactive drug, therapeutic support, supervised dosing, and hours in clinic. That complexity helps explain why many large pharmaceutical companies have not led first-generation psychedelic development. The commercial case has to solve delivery, not just product approval.

Plan for more than one access route

National HTA and reimbursement should remain the main access route because it offers the best chance of broad and equitable patient access. Psychedelic therapies may still need adapted assessment methods and delivery rules. Developers should also plan backup routes such as private insurance, patient-paid care, and charitable or philanthropic services, while keeping national reimbursement as the main goal.

Restricted routes may become the first real access channel if national reimbursement is slow or negative. Even with national coverage, local rollout can be slow and limited to a few sites. Private, charitable, or philanthropic services can sometimes move faster, generate early practice insight, and reach groups less connected to mainstream care. These routes work best as complements to national reimbursement, not substitutes.

How to plan before market entry

Europe can overwhelm small developers. Each country has its own reimbursement process, and psychedelic therapy adds unusual questions about scheduling, therapy time, site standards, and payment. Teams that plan mainly for North America can easily leave Europe too late.

Access planning should start with the patient group, priority countries, and most plausible market-access routes. From there, teams can map when decisions are needed and refine the commercial model as clinical development progresses. External advisors can help, but early engagement with the actual health-system decision makers matters most.

Market-access problems rarely have a single owner. Developers, payers, regulators, providers, and patient groups need early conversations about evidence gaps, service assumptions, and payment risk. If those gaps first appear at market entry, there may be too little time and too little trust to solve them before access stalls.

The Netherlands: capacity before reimbursement

Floris Wolswijk

Capacity is the bottleneck

Reimbursing psychedelic therapy is an important step, but it will not be enough. Even if approval, pricing, and integration go smoothly, the bigger issue may be a lack of therapists to meet demand.

Psychedelic therapy takes far more capacity than a standard prescription visit. Based on discussions with trial therapists and facilitators, many can manage about one dosing session per week. The work is emotionally demanding and requires preparation, presence during the session, and recovery time. At that rate, one therapist might support roughly 50 patients per year, or about 25 if each patient needs two sessions.

The Netherlands has 15,000 psychologists and 3,500 psychiatrists, treating around 1.5 million patients annually—an average of 80 per professional. Even if 1,000 therapists were trained in psychedelic therapy, they could only treat 50,000 people annually. While that may sound like a lot, it falls far short of demand. In the Netherlands, approximately 350,000 people suffer from treatment-resistant mental health conditions, including depression, PTSD, anxiety disorders, and alcohol addiction, who do not respond to standard care.

Developers are testing lighter delivery models to reduce this bottleneck. Some models shift more work to nurses or other trained healthcare professionals and use less psychotherapy around dosing. That may improve capacity, but it also moves away from the intensive models used in many trials. Health systems will need evidence on what is gained, what is lost, and which patients need higher-support care.

Retreatment changes the access model

Advocates often describe psychedelic therapy as a one-off treatment: take a dose, process the experience, and move on. That framing makes the model sound simpler than it is, closer to a procedure than to long-term psychiatric care.

Mental health rarely works that cleanly. Psychedelic therapy for PTSD may sometimes come closer to a one-course model, where effective trauma processing reduces the need for further treatment. Depression, anxiety, and addiction are different. They often involve ongoing stress, relapse risk, and changing life circumstances.

A single psychedelic session can produce large changes for some patients, but benefits may fade. If many patients need another session within one or two years, workforce demand rises quickly. Redosing is therefore not a minor follow-up question; it affects capacity planning, cost-effectiveness, and payer confidence.

Insurers and policymakers will look beyond the cost of one treatment course. If many patients need repeat sessions without durable outcome gains, the system takes on higher cumulative costs without reducing the pressure on other services. Retreatment assumptions therefore belong in the reimbursement model from the start.

Pressure on an overloaded system

Psychedelic therapy is entering a mental-health system already under strain. The Netherlands has long faced waiting lists, staff shortages, and rising costs.

Demand for mental-health services has increased, while burnout pushes professionals out of the field. That limits access before any new therapy is added.

Other psychiatric interventions, including rTMS and esketamine, already show the scaling problem. They can help some patients, but they require specialist staff, supervision, equipment, or dedicated facilities. Psychedelic therapy faces the same hurdle: it is not a simple prescription visit, but a time-intensive treatment that needs trained professionals.

The practical question is where the time comes from. No reserve workforce is waiting to deliver psychedelic therapy. Every multi-hour session uses time that could otherwise serve another patient. Without extra capacity, other parts of mental-health care may be squeezed.

Funding raises the same question. Will psychedelic therapy fit within existing mental-health budgets, or require additional money? If outcomes do not reduce later care needs, the system may add cost without reducing the overall burden. Reimbursement models need to test that risk.

Innovation inside system constraints

Psychedelic therapy is not the first mental-health treatment to show promise while facing access limits. Esketamine has regulatory approval for depression, yet many patients cannot obtain it because of cost, supervision, and delivery requirements. rTMS can help treatment-resistant depression, but equipment costs and trained-staff shortages limit scale.

Traditional psychotherapy faces the same constraint. It works for many patients, but therapist supply is limited and waiting lists are long. Psychedelic therapy does not escape that problem; it intensifies it if each patient needs many supervised hours.

If psychedelic therapy remains limited to specialist clinics, it may help selected patients without changing the broader mental-health system. Scaling before capacity is ready creates the opposite problem: demand rises before trained staff, facilities, and governance are in place. The access case will be stronger if therapies reduce later care needs, but that claim needs large programmes and long-term outcome data.

Can shorter or modified compounds help?

If psychedelic therapy is going to reach more people, delivery has to change. The current high-support model is slow, expensive, and dependent on a limited number of trained therapists. Even with reimbursement, demand could exceed supply.

Next-generation psychedelic treatments are one response to delivery pressure. Shorter-acting versions of MDMA or psilocybin could let teams treat more patients per room and per clinician day. The key question is whether shorter models preserve enough clinical benefit and safety.

Psychoplastogens offer a different route: medicines designed to keep therapeutic benefit while reducing or removing the hallucinogenic experience. If they can be prescribed more like conventional antidepressants, they may be easier for health systems to scale. They would not replace therapist-led psychedelic therapy, but they could reduce pressure on specialist rooms and trained teams.

Psychedelic therapy may help some patients who have exhausted other options. Reimbursement is only the first step. Without a plan for workforce, capacity, retreatment, and long-term outcomes, the system could shift costs rather than reduce the overall burden on mental-health services.

Europe: make sure trial participants can later access care

Josh Hardman

At the time of the source, several major programmes were underway in the United States, while the timeline for European approval and market access remained uncertain. The broader point still holds: if developers focus first on the U.S., European reimbursement and delivery planning can lag behind clinical development.

Marketing approval in a major market will be a milestone, but it will only start the access work. This is especially true in Europe, where national reimbursement and delivery decisions still determine whether patients can receive care.

This is why planning needs to start now. Developers, policymakers, payers, regulators, providers, patient groups, and advocacy organisations each control part of the access pathway. If they wait until approval, Europe risks having therapies that are authorised but difficult to deliver.

Psychedelic development programmes need data that HTA bodies can compare with standard care. That includes medium-term cost and benefit inputs, especially durability. European HTA bodies share some methods, but developers should still design evidence packages for the specific countries and assessors that matter most to launch.

Early scientific advice can shorten later appraisal timelines. Maignen and Kusel (2020) and Wang et al. (2024) found shorter NICE appraisal timelines among sponsors that used the UK's scientific-advice pathway.

Some barriers sit outside developer control. Many European mental-health systems are underfunded compared with other areas such as oncology. HTA models may also count healthcare costs and benefits more readily than wider societal effects. In the UK, for example, specialised treatment environments and trained professionals are already scarce. That makes service readiness and equitable access hard to assume, especially for therapies with high upfront costs and heavy logistics.

Other actors can help answer implementation questions. Government-funded or academic studies could test delivery models that reduce staff time, such as group preparation, group integration, simultaneous dosing, or other lower-intensity approaches. Those studies can make later reimbursement decisions less dependent on developer-sponsored evidence alone.

Post-approval public research can also compare therapies directly. In the United States, PCORI is funding a comparative effectiveness study of esketamine (Spravato) versus IV racemic ketamine in treatment-resistant depression. Similar studies would be useful in European tax-funded systems because payers need to know which intervention gives the best value, not only whether one product works.

The phrase multi-stakeholder approach can sound empty, but it fits here. Reimbursement depends on developers, payers, regulators, clinicians, patient groups, and policymakers understanding the same access problem from different positions. The value is the shared work of turning evidence into deliverable care.

Some developers are trying to avoid the hardest delivery questions by pursuing shorter-duration psychedelic-based medicines, leaner support models, or non-hallucinogenic psychoplastogens. Those approaches may reduce service burden, but they do not remove the need to prove clinical value, safety, and payer relevance.

Even shorter-acting psychedelics with leaner psychological support could struggle in Europe. Spravato is the cautionary example: despite major-company backing, reimbursement and availability across Europe and the UK remain uneven. Strong U.S. sales can still make a product commercially successful while European access stays patchy.

European patients may help generate evidence in early- and mid-stage trials without later gaining access to approved therapies. That risk grows when companies treat Europe mainly as a research setting and delay payer, delivery, and reimbursement planning until after U.S. launch decisions.

The practical response is early European payer engagement, clear patient-group involvement, and payment models that make access possible before a therapy reaches the market.

Advocacy: learn from HIV treatment access

Tadeusz Hawrot

Mental health has large unmet needs across Europe. Psychedelic therapies may help address some of those gaps, but access will require more than EMA approval. Each country still needs reimbursement decisions, delivery settings, trained staff, and practical referral routes.

Europe has strong early and mid-stage psychedelic research, supported by universities, hospitals, investigators, and study participants. The bottleneck is late-stage development. Without more Phase III programmes designed for European regulatory and payer needs, national reimbursement decisions may still add years before patients can access care.

Clinical advocacy may accelerate access. Researchers, clinical groups, and patient organisations can help explain why a therapy matters, where current care fails, and what evidence payers should consider.

The HIV treatment movement is a useful access analogy because it combined scientific literacy, public pressure, and inside-the-system policy work.

Activists built HIV/AIDS advocacy around strategies that still matter for mental-health access. They learned the science well enough to challenge regulators, companies, and research institutions on trial design, approval pathways, and policy.

They also used an inside-outside strategy. Public pressure brought attention to the crisis, while trained representatives worked with regulatory and funding agencies to change decisions.

Mental-health advocacy needs the same seriousness. Patients, families, clinicians, and researchers have to explain the cost of delay and the practical access conditions that would make new therapies useful rather than symbolic.

Transparency matters too. HIV/AIDS activists pushed for openness in drug pricing, trial data, and regulatory processes. Psychedelic and mental-health advocates can use the same instinct to keep promising therapies from becoming private-clinic products only.

HIV/AIDS activism also changed public perception. Early public debate framed HIV through stigma and moral judgement rather than public health. Activists reframed treatment access as a human-rights and health-system issue, then built political and financial support around that frame. Psychedelic therapies face a different history, but prohibition, underfunding, and misinformation still shape public attitudes. Advocacy needs to make the medical case without sliding into hype.

The HIV/AIDS response also shows the value of sustained political and financial support. Psychedelic and mental-health advocates need similar attention to research funding, late-stage trials, reimbursement pathways, and national health strategies.

How to Survive a Plague is a useful reference for this access history. It shows how ACT UP and TAG activists became serious policy actors by combining protest, technical knowledge, negotiation, and persistence.

PAREA's role is to build that kind of informed coalition for psychedelic therapy: people with lived experience, scientists, clinicians, and civil-society groups who can speak to policymakers before access decisions are already locked in.

The practical lesson is not to copy HIV activism exactly. It is to combine expertise, organisation, public pressure, and patient voice early enough that access is part of development, not an afterthought.

Czech Republic: link national advocacy to EU policy

Viktor Chvátal and Sumudu Gouri Boyina

Advocacy has to work at both EU and national levels. EU institutions can shape research, competitiveness, mental-health strategy, and cross-border coordination, but Member States remain responsible for public health and reimbursement. A useful advocacy message therefore needs two layers: a European case for mental-health innovation and national arguments that fit local budgets, service capacity, and payer rules.

EU policy can help national work, but it cannot replace it. Member States still need their own evidence, budget analysis, provider plans, and reimbursement arguments. A domestic cost-effectiveness study, for example, can support national decisions while giving EU-level discussions something concrete to build on.

The Czech Republic gives that strategy a plausible home. During its 2022 Presidency of the Council of the EU, it put mental health back on Europe's agenda through the governmental conference 'Resilient Mental Health in the European Union'. PsychedelicsEUROPE took part in the psychedelic-therapy discussion, and the country's research and policy ecosystem gives it a credible regional role.

The Czech Republic offers another useful example: a long tradition of evidence-informed policy on controlled or illicit substances. The Act on Psychomodulatory Substances came into force on January 1, 2025. In mental health care, the country was also early to provide ketamine therapy through PSYON clinic, now partially reimbursed by major public health insurance funds.

The gap was practical: reimbursement schemes, budgets, and delivery rules were still not central in EU or Member State discussions. EU interest in mental health was rising, but national lobbying was often fragmented and lacked clear objectives.

The Czech field also lacked a cost-effectiveness study that could support structured dialogue with regulators and payers. That kind of analysis matters because state authorities are used to discussing budget impact and value with representatives of established therapies.

Treatment providers in the Czech Republic were also not yet organised around a shared advocacy position. In a largely public healthcare system, that makes public-affairs strategy more important: providers need to explain what they want regulated, funded, and delivered.

Central and Eastern Europe adds another access context: PTSD linked to the war in Ukraine and migration across the region. PsychedelicsEUROPE co-organised a Czech-Ukrainian governmental event in May 2024 on psychedelic therapies for PTSD, with a follow-up event planned in 2025 to bring new data to decision makers, regulators, and payers.

Czech experts and advocates were also preparing a joint memorandum for the government after the 2025 parliamentary elections. The policy aim was to keep regulatory exchange alive and encourage a Dutch-style state committee to examine specific substances within psychedelic therapy.

What to take from these observations

The common thread is timing. Commercial strategy, payer evidence, workforce planning, advocacy, and country policy cannot wait until approval. If those pieces are handled late, the result may be a licensed therapy available only in a few sites or through private payment.

For teams planning access, the practical task is to decide which route they are building for, which country constraints matter first, and which evidence gaps could block reimbursement even after a positive clinical result.